Abstract| Volume 116, P82, December 2022

P035“No test” medication abortion: A systematic review

      This paper is only available as a PDF. To read, Please Download here.


      To summarize the effectiveness and safety outcomes of medication abortion performed without prior pelvic examination or ultrasound (“no test” medication abortion).


      We searched Medline, Scopus, Web of Science, Cochrane, CINAHL, Global Index Medicus, and CAB Direct databases to identify relevant studies prior to April 2022 using a peer-reviewed search strategy including terms such as “medication abortion” and “ultrasonography.” Experts in the field were contacted for unpublished data and ongoing studies. 2,423 studies were reviewed using Colandr. Studies were included if they presented clinical outcomes of medication abortion performed without prior pelvic examination or ultrasound. Studies with duplicate data were excluded. We abstracted successful abortion rates overall, as well as rates by gestational age through 63 days, 70 days and past 84 days. We abstracted complication rates, including the need for surgical evacuation, additional medications, blood transfusion, and ectopic pregnancy.


      We included 21 studies with a total of 10,693 patients with outcome data reported. The overall efficacy of “no test” medication abortion was 96.4%, 93.8% through 63 days of gestation and 95.2% through 70 days of gestation. The overall rate of surgical evacuation was 4.4%, need for additional misoprostol 2.2%, need for blood transfusion was 0.5%, and ectopic pregnancy was 0.06%.


      Medication abortion performed without prior pelvic examination or ultrasound is a safe and effective option for pregnancy termination.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect